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Ixazomib enhances parathyroid hormone–
induced β-catenin/T-cell factor signaling by 
dissociating β-catenin from the parathyroid 
hormone receptor
ABSTRACT The anabolic action of PTH in bone is mostly mediated by cAMP/PKA and Wnt-
independent activation of β-catenin/T-cell factor (TCF) signaling. β-Catenin switches the PTH 
receptor (PTHR) signaling from cAMP/PKA to PLC/PKC activation by binding to the PTHR. 
Ixazomib (Izb) was recently approved as the first orally administered proteasome inhibitor for 
the treatment of multiple myeloma; it acts in part by inhibition of pathological bone destruc-
tion. Proteasome inhibitors were reported to stabilize β-catenin by the ubiquitin-proteasome 
pathway. However, how Izb affects PTHR activation to regulate β-catenin/TCF signaling is 
poorly understood. In the present study, using CRISPR/Cas9 genome-editing technology, we 
show that Izb reverses β-catenin–mediated PTHR signaling switch and enhances PTH-induced 
cAMP generation and cAMP response element–luciferase activity in osteoblasts. Izb increases 
active forms of β-catenin and promotes β-catenin translocation, thereby dissociating β-catenin 
from the PTHR at the plasma membrane. Furthermore, Izb facilitates PTH-stimulated GSK3β 
phosphorylation and β-catenin phosphorylation. Thus Izb enhances PTH stimulation of β-
catenin/TCF signaling via cAMP-dependent activation, and this effect is due to its separating 
β-catenin from the PTHR. These findings provide evidence that Izb may be used to improve 
the therapeutic efficacy of PTH for the treatment of osteoporosis and other resorptive bone 
diseases.
INTRODUCTION
Long after Bauer and colleagues discovered the anabolic effect of 
parathyroid hormone (PTH) in 1929 (Bauer et al., 1929), recombi-
nant PTH(1-34) (teriparatide) was approved as the first anabolic 
agent for the treatment of osteoporosis in the United States in 2002, 
and no other anabolic drugs are on the market. The optimal use of 
PTH therapy in osteoporosis depends in part on our understanding 
of the regulation of PTH signaling to maintain the anabolic actions 
of PTH while mitigating its catabolic effects. PTH action in bone is 
mediated by type 1 PTH receptor (PTHR), a member of the G pro-
tein–coupled receptor superfamily. Stimulation of PTHR by PTH on 
osteoblasts leads to activation of Gαs and Gαq, with consequent 
induction of cAMP/protein kinase A (PKA) and phospholipase C 
(PLC)/PKC signaling pathways, which results in both osteoblast for-
mation and osteoclast resorption (Qin et al., 2004; Cheloha et al., 
2015). Whereas anabolic PTH effects in bone are mediated mostly 
through the cAMP/PKA signaling pathway, PLC/PKC signaling has 
been shown to be inhibitory to the osteoanabolic actions of PTH 
(Ogata et al., 2011). Wnt/β-catenin signaling controls bone forma-
tion and homeostasis by increasing osteoblast differentiation and 
inhibiting osteoclastogenesis (Gaur et al., 2005; Glass et al., 2005; 
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and carfilzomib directly stabilize β-catenin protein and increase free 
cytosolic β-catenin and β-catenin nuclear translocation (Qiang et al., 
2009; Hu et al., 2013). However, how proteasome inhibition regu-
lates the complex interplay between PTHR and β-catenin to in turn 
regulate β-catenin/TCF signaling has not been elucidated.
In the present study, we show that Izb reverses the β-catenin–
mediated PTHR signaling switch by enhancing PTH-induced cAMP 
formation and cAMP response element-luciferase (CRE-luc) reporter 
gene activity and reducing PTH-stimulated intracellular calcium mo-
bilization in osteoblasts. Izb enhances PTH-induced β-catenin/TCF 
signaling by separating β-catenin from the PTHR and promoting 
β-catenin translocation.
RESULTS
Knockout of β-catenin increases PTH-induced cAMP 
formation and reduces intracellular calcium in osteoblasts
Recent findings show that β-catenin switches the PTHR signaling by 
binding to the intracellular carboxyl-terminal region of the PTHR in 
both chondrocytes and HEK293 cells (Yano et al., 2013; Yang and 
Wang, 2015). In an initial set of experiments, we examined whether 
β-catenin also switched the PTHR signaling in osteoblasts. Saos2 
osteoblastic cells endogenously express both β-catenin and the 
PTHR (Wang et al., 2009). These cells were transfected with a clus-
tered regularly interspaced short palindromic repeats (CRISPR) con-
struct or CRISPR control plasmid. After 48 h of transfection, the cells 
were transferred into a 96-well plate with one cell per well by a serial 
dilution. Two single colonies were identified for knockout of β-
catenin expression in Saos2 cells (hereafter referred to as Saos2-β-
Cat-KO-3 and Saos2-β-Cat-KO-10 cells; Figure 1A), whereas no 
β-catenin expression was reduced in cells transfected with control 
plasmid (Saos2-β-Cat-Ctr; Supplemental Figure S1).
To assess the effect of β-catenin on PTH-induced Gαs/cAMP sig-
naling, we conducted PTH stimulation of cAMP generation in Saos2-
β-Cat-KO-3 cells (β-Cat KO) and their control cells (Saos2-β-Cat-
Ctr-1, WT Ctr). Knockout of β-catenin significantly increased 
PTH(1-34) (hereafter referred to as PTH) stimulation of cAMP forma-
tion (Figure 1B). To evaluate PTHR-mediated Gαq/PLC signaling, 
we measured intracellular calcium mobilization ([Ca2+]i), an index of 
PLC activity, in Saos2-β-Cat-KO-3 cells and Saos2-β-Cat-Ctr-1 cells 
loaded with the calcium-sensitive dye Fluo-4 AM. Knockout of β-
catenin markedly inhibited PTH-induced [Ca2+]i (Figure 1C). Similar 
results also occurred in Saos2-β-Cat-KO-10 and Saos2-β-Cat-Ctr-2 
cells (unpublished data). Collectively these data clearly demonstrate 
that knockout of β-catenin reverses the PTHR signaling switch to 
increase Gαs/cAMP signaling and reduce Gαq/PLC activation, 
which favors the anabolic PTH action in bone.
Izb enhances PTH-induced cAMP formation in a 
time- and concentration-dependent manner
We previously reported that proteasome inhibitors stabilized β-
catenin by the ubiquitin-proteasome pathway (Qiang et al., 2009; 
Hu et al., 2013). Because β-catenin switches PTHR signaling, we 
next determined whether Izb regulated PTHR activation. Izb alone 
was not able to stimulate cAMP formation (Supplemental Figure 
S2). However, pretreatment of Izb enhanced PTH stimulation of 
cAMP formation in Saos2 cells, which exhibited time and concentra-
tion dependence. Maximal stimulation by Izb was achieved at 3 h 
(Figure 2A), but prolonged Izb treatment tended to reduce its effect 
on PTH-induced cAMP formation. At the 3 h, Izb elicited a concen-
tration-dependent increase in PTH-induced cAMP formation over 
the range 12.5–100 nM (Figure 2B), but higher concentrations of Izb 
also decreased its effect on PTH stimulation of cAMP production. 
Liu et al., 2015). Our data and those from other groups show that 
β-catenin interacts with the PTHR and switches the PTHR signaling 
from Gαs/cAMP to Gαq/PLC activation (Yano et al., 2013; Yang and 
Wang, 2015). There is cross-talk between PTHR and frizzled receptor 
to regulate PTH action in bone (Wan et al., 2008; Romero et al., 
2010; Revollo et al., 2015). The low-density lipoprotein receptor–
related protein 6 (LRP6), one of frizzled’s coreceptors, is a key ele-
ment of the PTH signaling for regulating osteoblast activity (Wan 
et al., 2008; Revollo et al., 2015). PTHR directly interacts with 
Dishevelled to regulate β-catenin signaling and osteoclast differen-
tiation (Romero et al., 2010). PTH facilitates canonical Wnt signaling 
via inactivation of glycogen synthase kinase 3β (GSK3β) in osteo-
blasts to inhibit β-catenin sequestration (Suzuki et al., 2008). These 
findings highlight the role of β-catenin/T-cell factor (TCF) signaling 
in anabolic action of PTH in bone. It is unclear how β-catenin directly 
contributes to the osteoanabolic action of PTH.
β-Catenin is a multifunctional protein and does not contain a 
transmembrane domain (Nelson and Nusse, 2004; Stepniak et al., 
2009; Marie et al., 2014). Cadherins, which have a single-pass trans-
membrane domain, bind to β-catenin through their carboxyl-termi-
nal domain at the cytoplasmic tail. Thus β-catenin serves as a link 
between cadherins and the actin cytoskeleton to mediate the role of 
cadherins in cell adhesion (Nelson and Nusse, 2004; Stepniak et al., 
2009; Marie et al., 2014). In addition, β-catenin also binds to numer-
ous other proteins in a cadherin-independent manner (Bienz and 
Clevers, 2003; Yano et al., 2013; Yang and Wang, 2015). In bone, 
N-cadherin associates with β-catenin at the cell membrane to regu-
late osteoblastogenesis by limiting Wnt signaling. Revollo et al. 
(2015) reported that N-cadherin modulated LRP6-PTHR interaction, 
restrained the intensity of PTH-induced β-catenin signaling, and re-
duced bone formation in response to intermittent PTH administra-
tion. Moreover, N-cadherin restrains PTH’s repressive effects on 
sclerostin/SOST by regulating LRP6-PTHR interaction (Yang et al., 
2016). The interaction of N-cadherin with β-catenin causes increased 
cadherin abundance on the cell surface and results in β-catenin se-
questration at the plasma membrane (Stepniak et al., 2009; Marie 
et al., 2014). The outcome reduces β-catenin nuclear translocation 
and decreases TCF/lymphoid enhancer factor–dependent transcrip-
tional activity. Accordingly, blockade of β-catenin degradation may 
enhance PTH stimulation of β-catenin/TCF signaling.
The ubiquitin-proteasome pathway plays an important role in 
regulating and controlling bone metabolism (Murray et al., 1998; 
Garrett et al., 2003; Yang et al., 2015). The first-generation protea-
some inhibitor bortezomib has been used as an effective therapy for 
the treatment of multiple myeloma, a disease characterized by an 
increase in the activity of osteoclasts and a decrease in the function 
of osteoblasts adjacent to tumor cells in the bone marrow (Pennisi 
et al., 2009). Carfilzomib, a next-generation selective proteasome 
inhibitor, exhibits potent antimyeloma efficacy compared with bort-
ezomib (Herndon et al., 2013; Berenson et al., 2014). We previous 
reported that carfilzomib suppressed PTH stimulation of osteoclast 
differentiation and bone-resorptive activity to mitigate the catabolic 
effects of PTH (Yang et al., 2015). A significant limitation of treatment 
with bortezomib and carfilzomib is that both drugs are administered 
intravenously or subcutaneously, which is inconvenient for patients 
and increases treatment cost. Ixazomib (Izb) is a small-molecule pro-
teasome inhibitor that overcomes these limitations. In November 
2015, Izb became the first orally administered proteasome inhibitor 
approved in the United States as an effective therapy for multiple 
myeloma. This effect is mediated in part through inhibition of patho-
logic bone destruction (Kupperman et al., 2010; Garcia-Gomez et al., 
2014; Muz et al., 2016). Proteasome inhibitors such as bortezomib 
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with Izb, carfilzomib, or vehicle for the first 
3 h, followed by an additional 5 h of culture 
in Izb- or carfilzomib-free medium. Izb and 
carfilzomib exhibited increases in the free 
cytosolic β-catenin level in a concentration-
dependent manner (Figure 3A). In addition, 
Izb increased nuclear β-catenin expression 
(Figure 3B). An independent experiment per-
formed by confocal microscopy showed that 
Izb induced β-catenin translocation in Saos2 
cells, as shown by its accumulation in cytosol 
and nucleus (Supplemental Figure S5).
The PTHR is a seven-transmembrane do-
main protein, whereas β-catenin does not 
contain any transmembrane domain in its 
structure. Because Izb increases active forms 
of β-catenin and promotes β-catenin translo-
cation, we asked whether Izb was able to 
separate β-catenin from the PTHR at the 
plasma membrane. Saos2 cells were trans-
fected with pCDNA3.1 vector, hemaggluti-
nin (HA)-PTHR, and/or Flag–β-catenin as in-
dicated. After 48 h of transfection, the cells 
were treated with vehicle or Izb (100 nM) for 
3 h, followed by an additional 5 h of culture 
in Izb-free medium. The membrane proteins 
were isolated, and the interaction of Flag-β-
catenin with HA-PTHR was performed by im-
munoprecipitation assay. The result in Figure 
3C show that treatment with Izb reduced the 
interaction of β-catenin with the PTHR at the 
plasma membrane, further confirming that 
Izb promotes β-catenin translocation to 
cytosol and nucleus. As a complementary 
experiment, Saos2 cells were transiently 
transfected with green fluorescent protein 
(GFP)–PTHR. After 48 h of transfection, the 
cells were treated with vehicle or Izb as be-
fore. There was a colocalization of β-catenin with the PTHR at the 
plasma membrane in the absence of Izb, whereas Izb reduced this 
colocalization (Figure 3D). Collectively Izb enhanced PTH-induced 
cAMP generation due to the separation of β-catenin from the PTHR.
Izb regulation of the PTHR signaling is β-catenin dependent
To test whether the specificity of Izb effect on PTH-induced cAMP 
production is due to separation of β-catenin from the PTHR, we 
used both wild-type and β-catenin–knockout Saos2 cells. Indeed, 
Izb failed to enhance PTH-induced cAMP formation and reduce in-
tracellular calcium mobilization in β-catenin–knockout cells com-
pared with that of wild-type Saos2 control cells (Figure 4).
Izb promotes PTH-induced CRE-luc activity and cAMP 
response element–binding phosphorylation
We next determined the effect of Izb on cAMP/PKA downstream 
signaling in osteoblasts. The active catalytic subunit of PKA stimu-
lates CRE-luc activity (Castellone et al., 2005). Wild-type Saos2 con-
trol cells or Saos2-β-Cat-KO cells were infected with lentiviral parti-
cles containing CRE-luc reporter gene. The cells were pretreated 
with Izb (100 nM for 1 h) before PTH (100 nM) was added to the 
culture for another 2 h. The CRE-luc activity was then measured. As 
shown in Figure 5A, Izb itself was not able to stimulate CRE-luc ac-
tivity in wild-type control or β-catenin–knockout cells. However, 
Similar to other proteasome inhibitors (Qiang et al., 2009; Hu et al., 
2013), Izb but not PTH caused slight cytotoxicity when the cells were 
treated with it for a prolonged time or at higher concentrations 
(Supplemental Figure S3, A–C). To reduce the cytotoxicity of Izb, we 
pretreated Saos2 cells with Izb or vehicle for the first 3 h, followed 
by an additional 5 h of culture in Izb-free medium, which mimics the 
pulse treatment used in the clinic and avoids unselective cytotoxicity 
of proteasome inhibition (Boissy et al., 2008). As expected, this regi-
men of Izb not only enhanced PTH stimulation of cAMP formation, 
but it also reduced its cytotoxicity (Figure 2, C and D). To verify these 
results, we also found that Izb enhanced PTH-induced cAMP gen-
eration in mouse primary osteoblasts (Supplemental Figure S4).
Izb promotes PTH stimulation of cAMP formation by 
facilitating the dissociation of β-catenin from the PTHR
There are different cellular pools of β-catenin in the plasma mem-
brane, cytosol, and nucleus. In most cells, the majority of β-catenin is 
located at the plasma membrane in a complex with cadherins or 
other proteins (Stepniak et al., 2009; Marie et al., 2014). Previous find-
ings reported that both bortezomib and carfilzomib increased free 
and active forms of β-catenin in Saos2 cells (Qiang et al., 2009; Hu 
et al., 2013). We used an affinity-based E-cadherin–glutathione-S-
transferase (GST) pull-down assay to separate the free β-catenin from 
the pool of membrane-bound β-catenin. Saos2 cells were treated 
FIGURE 1: Knockout of β-catenin switches the PTHR signaling from Gαq/PLC to Gαs/cAMP 
activation. Saos2 cells in a six-well plate were transfected with CRISPR construct or control 
plasmid. After 48 h, the cells, which expressed only OFP reporter as visualized using an Evos 
machine, were transferred into a 96-well plate with one cell per well. (A) After ∼3 wk, two single 
colonies (Saos2-β-Cat-KO-3 and Saos2-β-Cat-KO-10 cells) were identified for knockout of 
β-catenin expression in Saos2 cells by Western blotting. Immunoblotting was performed with 
primary antibodies of mouse monoclonal β-catenin (β-Cat) antibody plus rabbit polyclonal actin 
antibody and then with secondary antibodies (goat anti-mouse antibody [red] plus goat 
anti-rabbit antibody [green]). Actin was used for loading control. (B, C) Saos2-β-Cat-KO-3 cells 
(β-Cat KO) and control Saos2-β-Cat-Ctr-1 cells (WT Ctr) were set up in a 24- or 96-well plate. 
After 24 h of culture, cells were serum starved overnight. PTH (100 nM) stimulation of 
intracellular cAMP accumulation (B) or PTH (1 µM) induction of intracellular calcium (C) was 
measured as described in Materials and Methods. Data are summarized as mean ± SE of 
triplicate measurements. n = 4. ap < 0.05, bp < 0.01, compared with WT Ctr cells treated with 
vehicle; cp < 0.05, dp < 0.01, compared with WT Ctr cells treated with PTH; ep < 0.05, fp < 0.01, 
compared with β-Cat KO cells treated with vehicle. 
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cells, and this change was not affected by Izb 
in these cells (Figure 5C), further confirming 
that effects of Izb on PTHR downstream 
events are β-catenin dependent and medi-
ated by the cAMP/PKA signaling pathway.
Izb enhances PTH stimulation of 
GSK3β phosphorylation at Ser-9 and 
β-catenin phosphorylation at Ser-675
The stability of β-catenin is regulated by a 
multiprotein complex, which includes ade-
nomatous polyposis coli, GSK3β, and axin. 
PKA phosphorylates GSK3β at the amino 
acid Ser-9, which inhibits its kinase activity 
and then inactivates the β-catenin destruc-
tion complex (Castellone et al., 2005; Suzuki 
et al., 2008). PTH induces β-catenin/TCF sig-
naling via inactivation of GSK3β in osteo-
blasts (Suzuki et al., 2008). Saos2 cells were 
pretreated with Izb (100 nM) for 2.5 h, and 
PTH (100 nM) was then added for another 30 
min. GSK3β functions upstream of β-catenin 
activation. As expected, Izb by itself has no 
effect on GSK3β phosphorylation at Ser-9 
(Figure 6A). PTH treatment increased GSK3β 
phosphorylation, and Izb further enhanced 
PTH stimulation of GSK3β phosphorylation.
PKA-phosphorylated β-catenin at Ser-
675 increases β-catenin accumulation in the 
cytosol, thereby promoting β-catenin down-
stream signaling (Taurin et al., 2006; Revollo 
et al., 2015). We hypothesized that Izb en-
hanced PTH-induced phosphorylated β-
catenin at this site. To test this idea, we pre-
treated Saos2 cells with Izb for 1 h. Then we 
added 100 nM PTH to culture for another 
2 h. The data in Figure 6B show that PTH 
stimulated β-catenin phosphorylation at Ser-
675. Izb but not PTH slightly increased total 
β-catenin abundance. However, Izb and 
PTH synergistically increased β-catenin (Ser-
675) phosphorylation, although Izb on its 
own had no notable effect on the phosphor-
ylation of β-catenin.
Izb promotes PTH-induced β-catenin/TCF signaling 
in osteoblasts
PTH-facilitated β-catenin/TCF signaling is cAMP/PKA dependent 
(Kulkarni et al., 2005; Suzuki et al., 2008). Our data show that Izb en-
hanced PTH-induced cAMP formation and promoted PTH stimula-
tion of GSK3β and β-catenin phosphorylation. These findings suggest 
an additional mechanism by which Izb enhances PTH-induced β-
catenin/TCF signaling in osteoblasts. To test this idea, we transfected 
Saos2 cells with TOPflash or FOPflash plasmid. The cells were treated 
with Izb for the first 3 h, followed by an additional 5 h culture in Izb-
free medium in the presence or absence of PTH for 8 h. After treat-
ment, the TOPflash and FOPflash reporter activities were measured. 
Both bortezomib and carfilzomib induce osteoblast differentiation via 
Wnt-independent induction of β-catenin translocation and activation 
of β-catenin/TCF signaling (Qiang et al., 2009; Hu et al., 2013). As 
we predicted, Izb by itself stimulated nuclear β-catenin expression 
and β-catenin/TCF signaling (Figure 7, A and B). Izb and PTH 
knockout of β-catenin significantly increased PTH-induced CRE-luc 
activity. Izb failed to enhance PTH stimulation of CRE-luc activity in 
β-catenin–knockout cells compared with wild-type control cells.
cAMP response element–binding (CREB) protein signaling plays a 
key role in regulating osteoblast activity and bone formation (Long 
et al., 2001). PTH can induce phosphorylation of CREB through the 
cAMP/PKA signaling pathway (Pearman et al., 1996; Revollo et al., 
2015). Saos2 wild-type cells were pretreated with Izb (100 nM for 2 h) 
before PTH (100 nM) was added to the culture for another 1 h. PTH 
markedly induced CREB phosphorylation (Figure 5B). Izb by itself had 
no effect on phosphorylation of CREB but facilitated PTH stimulation 
of CREB phosphorylation. Total CREB abundance was unaffected in 
each group. PKA inhibitor H89 or PKC inhibitor bisindolylmaleimide I 
(Bis I) alone had no effect on CREB phosphorylation (Supplemental 
Figure S6). However, H89 but not Bis I blocked Izb enhancement of 
PTH-induced CREB phosphorylation (Figure 5B). In addition, PTH sig-
nificantly stimulated CREB phosphorylation in β-catenin–knockout 
FIGURE 2: Izb enhances PTH-induced cAMP formation in a time- and concentration-dependent 
manner. (A) Time course of Izb on PTH-stimulated cAMP formation. Saos2 cells were seeded onto 
a six-well plate. After 90% confluence, the cells were transfected with Glosensor cAMP reporter 
plasmid (pGS-22F) using Lipofectamine 2000. At 36 h after transfection, cells were transferred 
into a 96-well plate and cultured for 14 h. The cells were serum starved overnight and then 
treated with vehicle or Izb (100 nM) for the indicated times, and PTH-induced cAMP formation 
was measured. The peak response time for cAMP formation is 14 min. (B) Concentration response 
of Izb on PTH-stimulated cAMP formation. At 3 h, Izb (12.5–100 nM) concentration dependently 
increased PTH stimulation of cAMP formation. (C) Pulse treatment of Izb increases of PTH-
stimulated cAMP formation. Saos2 cells were treated with Izb (100 nM) for 8 h or for the first 3 h 
followed by an additional 5 h of culture in Izb-free medium in Saos2 cells. (D) Pulse treatment of 
Izb reduces cytotoxicity. Saos2 cells were treated with Izb (100 nM) for 8 h or for the first 3 h 
followed by an additional 5 h of culture in Izb-free medium in the presence of PTH (100 nM) in 
Saos2 cells. Cytotoxicity was assessed by MTT assay as described in Materials and Methods. Data 
are summarized as mean ± SE of triplicate measurements. n = 3. ap < 0.05, bp < 0.01, compared 
with cells treated with vehicle; cp < 0.05, dp < 0.01, compared with cells treated with PTH.
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synergistically increased nuclear β-catenin 
levels and β-catenin/TCF activation. Similar 
results were also identified in mouse osteo-
blasts (Supplemental Figure S7). PKA inhibi-
tor H89 but not PKC inhibitor Bis I inhibited 
PTH-stimulated TCF reporter activity (Figure 
7B), confirming that PTH-stimulated β-
catenin/TCF signaling is cAMP/PKA depen-
dent. However, H89 only partially reversed 
the effect of Izb on PTH stimulation of β-
catenin/TCF activation. Furthermore, H89 
failed to affect Izb increase of free cytosolic 
β-catenin level, nuclear β-catenin expression 
(Supplemental Figure S8, A and B), and β-
catenin/TCF signaling (Supplemental Figure 
S8D). H89 also had no effect on β-catenin 
phosphorylation at Ser-675 in the presence 
of Izb (Supplemental Figure S8C). These 
data clearly demonstrate that the effect of 
Izb alone on β-catenin translocation and β-
catenin/TCF signaling is not related to a 
cAMP/PKA pathway. Together the results 
show that, in addition to being capable of 
promoting β-catenin translocation, Izb en-
hances PTH stimulation of β-catenin/TCF 
signaling via an increase in cAMP-depen-
dent signaling.
DISCUSSION
Although PTHR signaling pathways are be-
ing studied in increasing detail, the regula-
tion of PTHR functions has not been fully 
elucidated. The anabolic PTH effects on 
bone are mostly mediated by the Gαs/
cAMP signaling pathway, whereas Gαq/PLC 
activation may antagonize these osteoana-
bolic actions (Datta and Abou-Samra, 2009; 
FIGURE 3: Izb facilitates the separation of β-catenin from PTHR. (A) Izb increases free β-catenin 
protein levels. Left, top, Saos2 cells treated with vehicle, Izb (25, 100 nM), or carfilzomib (Cfz, 
12.5, 50 nM) for the first 3 h followed by an additional 5 h of culture in Izb- or Cfz-free medium. 
GST–E-cadherin was bound to free β-Cat, and the complexes were purified using GST beads. 
Immunoblotting was then performed with primary antibodies of mouse monoclonal β-Cat 
antibody plus rabbit polyclonal actin antibody and then with secondary antibodies (goat 
anti-mouse antibody and goat anti-rabbit antibody). Lack of actin expression suggests that the 
beads were washed completely. Left, bottom, immunoblotting conducted with total lysates with 
the same primary antibodies and secondary antibodies. Right, quantified free β-catenin levels in 
three independent experiments presented as mean ± SE. ap < 0.05, bp < 0.01, compared with 
cells treated with vehicle. (B) Izb increases nuclear β-catenin expression. Saos2 cells were treated 
with vehicle or Izb as in A. Left, nuclear 
proteins were prepared and β-catenin 
expression analyzed by immunoblotting. 
Right, quantified nuclear β-catenin levels in 
three independent experiments presented as 
mean ± SE. ap < 0.05, bp < 0.01, compared 
with cells treated with vehicle. (C) Saos2 cells 
were transfected with pCDNA3.1 vector, 
HA-PTHR, and/or Flag-β-Cat as indicated. 
After 48 h of transfection, the cells were 
treated with vehicle or Izb (100 nM) as before. 
Left, the plasma membrane proteins were 
isolated, and the interaction of Flag-β-Cat 
with HA-PTHR measured. Right, coIP of 
β-catenin with PTHR in three independent 
experiments normalized to HA-PTHR band. 
bp < 0.01, compared with cells treated with 
vehicle. (D) Saos2 cells were transfected with 
GFP-PTHR. After 48 h, the cells were treated 
with vehicle or Izb (100 nM) as before. The 
cells were fixed, stained, and visualized for 
colocalization of PTHR with β-catenin by 
confocal microscopy. Representative of three 
independent experiments performed with 
similar results. Scale bar, 10 µm.
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important question of whether the interven-
tion of β-catenin interaction with PTHR in 
osteoblasts has a similar effect to alter PTH-
induced PTHR signaling. Proteasome inhibi-
tors such as bortezomib and carfilzomib, 
which have been used to treat multiple my-
eloma patients, were shown to directly sta-
bilize β-catenin protein and increase β-
catenin nuclear translocation (Qiang et al., 
2009; Hu et al., 2013). In the present study, 
we chose Izb, the first orally administered 
proteasome inhibitor for the treatment of 
multiple myeloma, because it has the po-
tential to treat resorptive bone diseases 
such as osteoporosis. We found that Izb in-
creased active β-catenin expression and 
translocation (Figure 3 and Supplemental 
Figure S5). Most importantly, we found, us-
ing coimmunoprecipitation (coIP) and con-
focal microscopy, that Izb was able to sepa-
rate β-catenin from the PTHR at the cell 
membrane. Pretreatment of Izb increased 
PTH-stimulated cAMP production and re-
duced PTH-induced PLC activity (Figure 4 
and Supplemental Figure S4), demonstrat-
ing that Izb can inhibit the PTHR signaling switch to increase cAMP 
formation in osteoblasts by promoting the dissociation of β-catenin 
from the PTHR. To the best of our knowledge, this is the first report 
showing how a proteasome inhibitor regulates PTHR signaling by 
dissociating β-catenin from the PTHR.
It is established that PTH-induced β-catenin/TCF signaling is 
cAMP/PKA dependent (Kulkarni et al., 2005; Suzuki et al., 2008). 
CRE-luc activity and CREB phosphorylation are downstream events 
that depend on cAMP/PKA activation. We demonstrated that Izb by 
itself had no effect on CRE-luc activity and CREB phosphorylation 
but enhanced PTH stimulation of CRE-luc activity and phosphoryla-
tion of CREB (Figure 5). Furthermore, Izb and PTH synergistically 
increased GSK3β phosphorylation at Ser-9 and phosphorylated β-
catenin at Ser-675 (Figure 6), the outcome of which results in β-
catenin translocation to the nucleus. It is known that PTH-induced 
β-catenin/TCF activation takes >6 h. Similar to other proteasome 
inhibitors, Izb treatment in cells for >3 h has some cytotoxicity 
(Boissy et al., 2008). To maintain Izb biological activity and avoid its 
toxicity, Saos2 cells received Izb for the first 3 h, followed by an ad-
ditional 5 h of culture in Izb-free medium. Our findings show that Izb 
enhanced PTH-induced β-catenin/TCF signaling without inducing 
cytotoxicity (Figures 2 and 7). Therefore our work reveals a novel 
role for Izb in regulating PTH-induced β-catenin/TCF signaling via 
the cAMP/PKA-dependent pathway.
The increase of cytosolic and nuclear β-catenin by proteasome 
inhibition is via its specific inhibition of β-catenin degradation but 
independent of Wnt ligands and not related to GSK3β phosphory-
lation (Qiang et al., 2009). In the present study, we demonstrated 
that Izb by itself does not affect GSK3β phosphorylation at Ser-9 
and β-catenin phosphorylation at Ser-675. Thus the underlying 
mechanisms by which Izb induces β-catenin/TCF signaling are not 
fully understood. Proteasome inhibition can stabilize numerous 
proteins. PTHR directly interacts with Dishevelled to regulate β-
catenin signaling (Romero et al., 2010). Zhou et al. (2016) recently 
reported that ubiquitin-specific protease 4 strongly inhibited 
Wnt/β-catenin signaling by removing lysine-63 linked polyubiquitin 
chain from Dishevelled and antagonized osteoblast differentiation 
Ogata et al., 2011). Additional anabolic signaling by PTH action in-
volves the canonical β-catenin pathway, which is independent of 
Wnt. Therefore manipulating PTHR signaling by shifting Gαq/PLC 
to Gαs/cAMP activation and increasing β-catenin/TCF signaling 
represents a means of maintaining the anabolic actions of PTH.
Sequences located at the carboxyl terminus of PTHR control its 
signaling (Datta and Abou-Samra, 2009; Romero et al., 2011). PTHR 
has a PSD-95/Discs large/ZO-1 (PDZ) motif located in the last four 
amino acids, which interact with NHERF1 and NHERF2 (Romero 
et al., 2011; Vilardaga et al., 2011). As originally described by Mahon 
et al. (2002), NHERF2, a NHERF1 homologue, markedly inhibits ad-
enylyl cyclase by stimulating inhibitory Gαi proteins in PS120 cells 
transfected with the PTHR. In contrast, no differences of PTH-stimu-
lated cAMP formation were noted between wild-type and NHERF1-
null proximal tubule cells (Cunningham et al., 2005) in the presence 
or absence of NHERF1. In ROS17/2.8 cells or primary osteoblasts, 
NHERF1 increases PTH-stimulated cAMP accumulation (Wheeler 
et al., 2008; Wang et al., 2013). Moreover, truncation of the car-
boxyl-terminal region of the PTHR that lacks determinants for stable 
β-arrestin association (PTHR-480stop) enhances PTH stimulation of 
adenylyl cyclase but not PLC (Iida-Klein et al., 1995; Wang et al., 
2007). In contrast to the aforementioned regulatory proteins, β-
catenin specifically binds to the intracellular carboxyl-terminal re-
gion of the PTHR and switches the PTHR signaling from Gαs/cAMP 
to Gαq/PLC activation in chondrocytes and HEK293 cells (Yano 
et al., 2013; Yang and Wang, 2015). As an initial step, we deter-
mined whether this signaling switch by β-catenin also occurred in 
osteoblasts. To that end, we generated a β-catenin–knockout cell 
line in osteoblasts using CRISPR/Cas9 genome-editing technology. 
Our data showed that knockout of β-catenin (i.e., zero expression of 
β-catenin) significantly increased PTH-induced cAMP formation, 
whereas PTH-stimulated PLC activity was markedly reduced in these 
knockout cells compared with cells transfected with CRISPR/Cas9 
control plasmid (Figure 1). These data are consistent with a previous 
study, using small interfering RNA, demonstrating that knockdown 
of β-catenin (i.e., reduction of β-catenin expression) inhibited the 
PTHR signaling switch (Yano et al., 2013). These findings raised an 
FIGURE 4: Izb blocks β-catenin–mediated PTHR signaling switch. Saos2-β-Cat-KO-3 cells 
(β-Cat KO) and their control cells (Saos2-β-Cat-Ctr-1, WT Ctr) were seeded onto a 24- or 96-well 
plate. After confluence, the cells were serum starved overnight and then pretreated with Izb 
(100 nM) for 3 h. PTH stimulation of cAMP formation (A) and intracellular calcium (B) were 
measured. Data are summarized as mean ± SE of triplicate measurements. n = 3. ap < 0.05, 
bp < 0.01, compared with WT Ctr cells treated with vehicle; cp < 0.05, dp < 0.01, compared with 
WT Ctr cells treated with PTH; ep < 0.05, fp < 0.01, compared with WT Ctr cells treated with Izb; 
gp < 0.05, hp < 0.01, compared with β-Cat KO cells treated with vehicle; ip < 0.05, jp < 0.01, 
compared with β-Cat KO cells treated with PTH; kp < 0.05, lp < 0.01, compared with β-Cat KO 
cells treated with Izb. 
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and mineralization through Dishevelled 
degradation. Therefore we do not exclude 
the possibility that Izb enhancement of PTH 
stimulation of β-catenin/TCF signaling may 
be related to its inhibition of Dishevelled 
degradation. In addition, PTHR activation, 
desensitization, endocytosis, and recycling 
proceed in a cyclical manner. We previously 
reported that PTHR recycling was complete 
by 2 h after stimulation with PTH(1-34), a 
biologically active peptide fragment, sug-
gesting the PTHR trafficking is different 
from that of β-catenin. However, PTH(7-34), 
which does not activate the PTHR but pro-
motes receptor internalization, down-regu-
lates the PTHR by a ubiquitin-sensitive 
pathway (Sneddon et al., 2003; Alonso 
et al., 2011). Continuous and high-dose 
PTH(1-34) causes bone resorption and hy-
percalcemia (Qin et al., 2004; Cheloha 
et al., 2015). Future investigations will need 
to assess the roles of proteasome inhibition 
on prolonged PTH treatment in induction 
of both cAMP formation and β-catenin/TCF 
signaling in bone cells.
On the basis of the present findings and 
generally accepted roles of proteasome in-
hibitor and β-catenin/TCF, we propose a 
model (Figure 8) for the effect of Izb on reg-
ulation of PTHR signaling cascade in bone. 
According to this notion, Izb regulates PTHR 
signaling by dissociating β-catenin from the 
PTHR to enhance PTH-induced β-catenin/
TCF activity. Such an effect is cAMP/PKA de-
pendent. Izb has been applied for the treat-
ment of both the tumor burden and bone 
loss associated with multiple myeloma. 
Whereas our previous study emphasized 
that proteasome inhibition mitigated the 
catabolic effect of PTH on bone by sup-
pressing PTH-induced osteoclast differenti-
ation and bone-resorptive activity (Yang 
et al., 2015), the present study demon-
strates that Izb can regulate the PTHR sig-
naling in osteoblasts, which favors anabolic 
PTH action in bone. These findings warrant 
further investigation of this combination of 
PTH and Izb on osteoblast differentiation 
FIGURE 5: Izb enhances PTH-induced CRE-luc activity and CREB phosphorylation. (A) Knockout 
of β-catenin increases PTH-induced CRE-luc activity. Saos2-β-Cat-KO-3 cells (β-Cat KO) and their 
control cells (Saos2-β-Cat-Ctr-1, WT Ctr) were seeded onto a 24-well plate. After cells reached 
80% confluence, the cells were infected with lentiviral particles of CRE-luc reporter and cultured 
for 48 h. The cells were serum starved overnight and then pretreated with Izb (100 nM for 1 h) 
before PTH (100 nM) was added to the culture for another 2 h. PTH induction of CRE-luc activity 
in each group was measured as described in Material and Methods. Data are summarized as 
mean ± SE of triplicate measurements. n = 3. ap < 0.05, bp < 0.01, compared with WT Ctr cells 
treated with vehicle; cp < 0.05, dp < 0.01, compared with WT Ctr cells treated with PTH; 
ep < 0.05, fp < 0.01, compared with WT Ctr cells treated with Izb; gp < 0.05, hp < 0.01, 
compared with β-Cat KO cells treated with vehicle; ip < 0.05, jp < 0.01, compared with β-Cat KO 
cells treated with PTH; kp < 0.05, lp < 0.01, compared with β-Cat KO cells treated with Izb. 
(B) Izb enhancement of PTH-induced CREB phosphorylation is cAMP/PKA dependent. Saos2-β-
Cat-Ctr-1 cells (WT Ctr) were pretreated with Izb (100 nM for 2 h) before PTH (100 nM) was 
added to the culture for another 1 h in the presence or absence of PKA inhibitor H89 (10 µM) or 
PKC inhibitor Bis I (10 µM) for 1 h and 15 min. Left, PTH-induced CREB phosphorylation and 
total CREB expression (loading control). Right, quantified CREB phosphorylation and total CREB 
expression in four independent experiments presented as mean ± SE. ap < 0.05, bp < 0.01, 
compared with cells treated with vehicle; cp < 0.05, dp < 0.01, compared with cells treated with 
PTH; ep < 0.05, fp < 0.01, compared with cells treated with Izb; gp < 0.05, hp < 0.01, compared 
with cells treated with PTH plus Izb. (C) Izb fails to affect PTH stimulation of CREB 
phosphorylation in β-catenin–knockout cells. 
Saos2-β-Cat-KO-3 cells (β-Cat KO) cells were 
pretreated with Izb (100 nM for 2 h) before 
PTH (100 nM) was added to the culture for 
another 1 h. Left, PTH stimulation of CREB 
phosphorylation. Right, quantified CREB 
phosphorylation and total CREB expression 
in three independent experiments presented 
as mean ± SE. ap < 0.05, bp < 0.01, compared 
with cells treated with vehicle; cp < 0.05, 
dp < 0.01, compared with cells treated with 
PTH; ep < 0.05, fp < 0.01, compared with 
cells treated with Izb. 
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(Carlsbad, CA). Glosensor cAMP reporter 
plasmid (pGS-22F) was purchased from Pro-
mega (Madison, WI). Protease inhibitor 
cocktail Set I, H89, and Bis I were from 
Calbiochem (San Diego, CA). The Cyclic 
AMP Direct EIA Kit was purchased from 
Arbor Assays (Ann Arbor, MI). Ionomycin 
was from EMD Millipore (Billerica, MA). All 
other reagents were from Sigma-Aldrich (St. 
Louis, MO).
Cell culture
Saos2 cells, a human osteoblast–like cell line, 
were purchased from the American Type 
Culture Collection (ATCC; Manassas, VA) 
and cultured in DMEM/F-12 with 10% fetal 
bovine serum (FBS), 100 U/ml penicillin, and 
100 μg/ml streptomycin. MC4 osteoblastic 
cells (subclone 4 of MCT3-E1; ATCC) were 
cultured in α-MEM with 10% FBS in the pres-
ence of 50 μg/ml ascorbic acid for 5 d and 
then used in the experiments. All cells were 
maintained at 37°C in a humidified atmo-
sphere of 5% CO2 and 95% air.
Primary osteoblast culture
All of the experiments using mice for gener-
ation of primary osteoblasts were performed 
according to the protocol approved by the 
Animal Care and Use Committee of Thomas 
Jefferson University. Generation of primary 
osteoblast cultures was described previously 
(Yang et al., 2015). Briefly, calvariae were re-
moved from 2- to 3-d-old C57BL/6 mice and 
digested with 1 mg/ml collagenase type II 
and 0.25% trypsin-EDTA. Cells released 
from the second and third digestions were 
grown in α-MEM supplemented with 10% 
FBS, 100 U/ml penicillin, and 100 μg/ml 
streptomycin. After trypsinization of the con-
fluent cells, differentiating osteoblasts were 
cultured in the presence of 50 μg/ml ascorbic acid for 7 d and used 
in the experiments.
cAMP formation and detection
Saos2 cells were transfected with Glosensor cAMP reporter plasmid 
(pGS-22F) in a six-well plate by Lipofectamine 2000 following the 
manufacturer’s instruction. After 36 h of transfection, cells were 
transferred into a 96-well plate. The confluent cells were then 
treated with vehicle or Izb (100 nM) at the indicated time points. 
After treatment, cells were incubated with luciferin for 20 min at 
room temperature, and then PTH or vehicle was added. Lumines-
cence arising from intracellular cAMP binding to the Glosensor re-
porter protein was measured in real time at 2-min intervals for 
60 min using a plate reader (Synergy-2; Gidon et al., 2014; Carter 
et al., 2015). The peak response time occurred by 16 min.
Additional cAMP measurements were performed in primary os-
teoblasts and Saos2-β-Cat-KO cells and Saos2-β-Cat-Ctr cells. These 
cells were treated with vehicle or Izb (100 nM for 3 h). PTH (100 nM 
for 15 min)-induced cAMP formation was detected using the cyclic 
AMP Direct EIA Kit (Arbor Assays) following the supplier’s instruc-
tions. The samples were analyzed by using a cAMP standard curve.
and osteogenesis in vitro and therapeutic efficacy in animal models 
of osteoporosis.
MATERIALS AND METHODS
Human [Nor8,18,Tyr34]PTH(1-34) was purchased from Bachem Cali-
fornia (Torrance, CA). Carfilzomib was purchased from LC Laborato-
ries (Woburn, MA), and Izb was obtained from Selleck Chemicals 
(Houston, TX). Both drugs were prepared in a 10 mM stock solution 
in dimethyl sulfoxide (DMSO) and diluted in plain medium just be-
fore use. Antibodies of β-catenin phosphorylation at Ser-675, 
phospho-GSK3β (Ser-9), GSK3β, phospho-CREB, and CREB were 
obtained from Cell Signaling Technology (Danvers, MA). HA.11 as-
cites monoclonal antibody (mAb) and HA.11 monoclonal affinity 
matrix were purchased from Covance (Berkeley, CA). Actin poly-
clonal antibody and lamin B1 mAb were from Santa Cruz Biotech-
nology (Santa Cruz, CA). Mouse monoclonal β-catenin antibody 
and Fluo-4 AM were obtained from BD Biosciences (San Jose, CA). 
Lentiviral particles of reporter gene CRE-luc were from Qiagen 
(Germantown, MD). GeneArt CRISPR Nuclease Vector with orange 
fluorescent protein (OFP) reporter kit (A21174), α-MEM, Opti-
MEM, and Lipofectamine 2000 were purchased from Invitrogen 
FIGURE 6: Izb facilitates PTH stimulation of GSK3β and β-catenin phosphorylation. (A) Saos2 
cells were seeded onto a six-well plate. After confluence, the cells were serum starved overnight 
and then pretreated with Izb (100 nM) for 2.5 h, and PTH (100 nM) was then added to the 
culture for another 30 min. Left, PTH-induced GSK3β phosphorylation and total GSK3β 
expression. Right, quantified GSK3β phosphorylation at Ser-9 and total GSK3β expression in 
four independent experiments presented as mean ± SE. (B) Saos2 cells were grown in a six-well 
plate and cultured as before. The cells were pretreated with Izb (100 nM) for 1 h, and PTH 
(100 nM) was then added to the culture for another 2 h. Left, PTH-induced β-catenin 
phosphorylation at Ser-675 and total β-catenin expression. Actin was used for loading control. 
Right, quantified β-catenin phosphorylation and total β-catenin expression in four independent 
experiments presented as mean ± SE. ap < 0.05, bp < 0.01, compared with cells treated with 
vehicle; cp < 0.05, dp < 0.01, compared with cells treated with PTH; ep < 0.05, fp < 0.01, 
compared with cells treated with Izb. 
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Cell viability assay
Cell viability was measured as described 
previously (Yang et al., 2015). Briefly, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide (MTT) was added to each 
well at a final concentration of 500 μg/ml. 
The cells were further incubated for 1 h at 
37°C in a 5% CO2 atmosphere, and the liq-
uid in the wells was subsequently removed. 
DMSO was then added to each well, and 
the absorbance was measured at 570 nm.
Knockout of β-catenin gene expression 
in Saos2 cells
Constitutive β-catenin expression in Saos2 
cells was knocked out using the CRISPR/Cas9 
genome-editing technique. Table 1 lists the 
double-stranded oligonucleotides encoding 
a CRISPR targeting RNA (crRNA) of β-catenin 
that allows sequence-specific targeting of the 
Cas9 nuclease. The double-stranded oligo-
nucleotides were cloned into linearized 
GeneArt CRISPR nuclease vectors with an 
OFP reporter following the manufacturer’s 
protocol. Saos2 cells were seeded into a six-
well plate. After cells reached 90% conflu-
ence, CRISPR plasmid or control plasmid was 
transfected into the cells using Lipofectamine 
2000 following the manufacturer’s protocol. 
Two days after the transfection, the cells were 
counted and seeded into a 96-well plate with 
one cell per well by a serial dilution. OFP re-
porter was applied to monitor transfection 
efficiency in cells for fluorescence-based 
tracking using an Evos machine (Invitrogen). 
After ∼3 wk, Western blotting was used to 
screen β-catenin expression in cells. Zero ex-
pression of β-catenin was identified in two 
single colonies when the cells were trans-
fected with CRISPR construct, whereas β-
catenin expression was not changed in cells 
transfected with the control plasmid.
Cell fractionation
Membrane and nuclear proteins were prepared by fractionating cell 
lysates using differential centrifugation at 4°C as described previ-
ously (Wang et al., 2008; Hu et al., 2013). Briefly, cells treated with 
Izb, PTH, or vehicle were harvested in hypotonic buffer (10 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.4, 1 mM 
MgCl2, 0.5 mM CaCl2, 1 mM EDTA) supplemented with protease 
inhibitor cocktail set I and then homogenized by 30 strokes of a 
Dounce homogenizer. After removal of the nuclear pellet, lysates 
were separated into cytosolic and membrane fractions by ultracen-
trifugation (100,000 × g) for 60 min. The membrane proteins were 
used for the interaction of β-catenin with the PTHR, and the nuclear 
proteins were subjected to immunoblot analysis for β-catenin 
expression.
Immunoprecipitation and immunoblot analysis
The plasma membrane proteins were solubilized in immunoprecipi-
tation assay buffer (1% Nonidet P-40, 0.5% Na deoxycholate, 0.1% 
SDS, 50 mM Tris, pH 7.4, and 150 mM NaCl) supplemented with 
Intracellular calcium assay
Saos2 cells were seeded into poly-d-lysine–coated 96-well plates 
and grown to confluence. The cells were then treated with vehicle or 
Izb (100 nM) for 3 h. After treatment, the cells were loaded with 2 
μM Fluo-4 AM according to the manufacturer’s protocol. PTH or 
vehicle was added by an automated pipetting system in triplicate, 
and the 525-nm signals were generated by excitation at 485 nm 
with a Flex Station II (Molecular Devices, Sunnyvale, CA) as previ-
ously reported (Deshpande et al., 2014). Maximal Ca2+ response 
was determined by stimulating the cells with 1 μM ionomycin. The 
net peak Ca2+ response was calculated using the equation (maxi-
mum agonist-induced fluorescence units) − (basal fluorescence 
units).
CRE-luc assay
Saos2 cells were infected with lentiviral particles of CRE reporter. 
After 48 h, the cells were serum starved overnight and then treated 
with Izb, PTH, or vehicle at the indicated time points. The CRE-luc 
activity was detected as previously described (Yan et al., 2011).
FIGURE 7: Izb facilitates PTH-induced Wnt/β-catenin signaling. (A) Izb enhances PTH-stimulated 
nuclear β-catenin expression. Saos2 cells were treated with Izb (100 nM) for the first 3 h, 
followed by an additional 5 h of culture in Izb-free medium in the presence or absence of PTH 
(100 nM) for 8 h. Left, nuclear proteins were prepared and β-catenin expression was analyzed by 
immunoblotting. Right, quantified nuclear β-catenin expression in four independent experiments 
presented as mean ± SE. ap < 0.05, bp < 0.01, compared with cells treated with vehicle; 
cp < 0.05, dp < 0.01, compared with cells treated with PTH; ep < 0.05, fp < 0.01, compared with 
cells treated with Izb. (B) Izb promotes PTH-induced TCF reporter activity. Saos2 cells were 
seeded into a 12-well plate. After 90% confluence, the cells were transfected with TOPflash or 
FOPflash plasmid. At 36 h after transfection, the cells were serum starved for 12 h and then 
treated with Izb for the first 3 h, followed by an additional 5 h of culture in Izb-free medium in 
the presence or absence of PTH (100 nM), PKA inhibitor H89 (5 µM), or PKC inhibitor Bis I (5 µM) 
for 8 h. The β-catenin/TCF activation was measured as described in Materials and Methods. 
Data are summarized as mean ± SE of triplicate measurements. n =3. ap < 0.05, bp < 0.01, 
compared with cells treated with vehicle; cp < 0.05, dp < 0.01, compared with cells treated with 
PTH; ep < 0.05, fp < 0.01, compared with cells treated with PTH plus Izb.
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GST–E-cadherin pull-down assay
The GST–E-cadherin binding assay was performed as described 
(Qiang et al., 2009). The β-catenin–binding site of E-cadherin was 
cloned as a GST-fusion protein, and complexes were purified using 
GST beads. GST–E-cadherin was used to precipitate uncomplexed 
β-catenin from 500 μg of cell lysates. The free β-catenin fraction 
detected by immunoblotting represents active forms of β-catenin 
(Qiang et al., 2009).
Fluorescence staining
Saos2 cells were grown on glass coverslips and then transfected 
with GFP-PTHR. After 40 h, the cells were incubated with vehicle or 
Izb (100 nM) for 3 h, followed by an additional 5 h of culture in Izb-
free medium. The cells were rinsed in phosphate-buffered saline 
(PBS), fixed on 4% paraformaldehyde for 10 min, and then permea-
bilized with 0.2% Triton X-100 for 15 min at room temperature. 
Blocking was performed by incubating the cells for 1 h at room tem-
perature in 10% goat serum in PBS. Anti–β-catenin mouse mAb di-
luted (1:250) in blocking buffer was applied to the specimens for 1 h 
at room temperature. Alexa Fluor 546–tagged goat anti-mouse sec-
ondary antibody diluted 1:1000 was applied under the same condi-
tions as the primary antibody. Nucleus staining was performed with 
DRAQ5. Coverslips were mounted for confocal microscopy (Wang 
et al., 2008).
TOPflash/FOPflash activity assay
Saos2 cells or MC4 cells were transfected with TOPflash or FOPflash 
in a 12-well plate by using Lipofectamine 2000 according to the 
manufacturer’s protocol. After 36 h of transfection, cells were serum 
starved for 12 h and then treated with the indicated reagents. Eight 
hours after treatment, cells were lysed with reporter lysis buffer (Pro-
mega). The cell lysates were then drawn four times through a 
21-gauge needle attached to a 1-ml syringe. The supernatants were 
transferred to a 96-well plate. The luminescence of each well was 
recorded after addition of BioGlo Luciferase substrate (Promega). 
The ratio of TOP/FOP signal was calculated and normalized to con-
trol conditions.
Statistical analysis
The data are presented as mean ± SE of triplicate measurements. In 
the figures, n indicates the number of independent experiments. 
Statistical analysis between control and treated groups was per-
formed using Student’s t test. Multiple comparisons in one or two 
types of cells were evaluated by one-way or two-way analysis of 
variance followed by Bonferroni’s posttest (Prism; GraphPad). p < 
0.05 was considered sufficient to reject the null hypothesis.
protease inhibitor cocktail set I. HA beads were added to equal 
amounts of soluble membrane proteins in each group. Immunopre-
cipitated proteins, nuclear proteins, or total lysates (Wang et al., 
2008; Hu et al., 2013) were analyzed by SDS–polyacrylamide gels 
and transferred to Immobilon-P membranes (Millipore) using the 
semidry method (Bio-Rad). Membranes were blocked with 3% bo-
vine serum albumin in Tris-buffered saline/Tween 20 buffer at room 
temperature for 1 h and incubated with different antibodies over-
night at 4°C. The membranes were then washed and incubated with 
IRDye 800CW goat anti-rabbit immunoglobulin G (IgG) or IRDye 
680RD goat anti-mouse IgG at room temperature for 1 h. Band in-
tensity was quantified using the LI-COR Odyssey system (Yang and 
Wang, 2015).
Double-stranded 
cloning Oligo Sequence
Accession 
number
β-Catenin Forward: 5′-TCCCACTAAT-
GTCCAGCGTT
NM_001904
Reverse: 5′-AACGCTGGA-
CATTAGTGGGA
Control Forward: 5′-CATTTCT-
CAGTGCTATAGA
Reverse: 5′-TCTATAG-
CACTGAGAAATG
TABLE 1: CRISPR sequences for knockout of human β-catenin.
FIGURE 8: Model of Izb regulation of PTHR signaling cascade in 
bone. Both PTH and Izb are able to induce β-catenin (β-Cat)/TCF 
signaling. Izb stabilizes β-Cat by inhibiting its proteasome 
degradation. β-Cat–mediated PTHR signaling switch is blocked by Izb 
due to its promoting of β-Cat translocation, thereby dissociating 
β-Cat from the PTHR. Izb facilitates PTH stimulation of CREB 
phosphorylation, β-Cat (Ser-675) phosphorylation, GSK3β (Ser-9) 
phosphorylation, and TCF/Lef activity through a cAMP/PKA signaling 
pathway. Collectively these findings suggest that the combination of 
PTH and Izb favors the anabolic PTH action in bone.
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